Elan Corporation PLC: Neuroimaging Technique Supports Reduction in Amyloid-Beta in Brains of Patients Suffering from Alzheimer's Disease Treated with Bapineuzumab

DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer’s disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.